GH Research (NASDAQ:GHRS) Stock Price Up 3.1% – Should You Buy?

GH Research PLC (NASDAQ:GHRS) shares shot up 3.1% on Monday . The company traded as high as $9.05 and last traded at $8.88. 18,510 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 79,195 shares. The stock had previously closed at $8.61.

Analyst Upgrades and Downgrades

GHRS has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price target on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Trading Up 1.0 %

The company’s 50-day moving average price is $7.72 and its two-hundred day moving average price is $10.40.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. As a group, sell-side analysts expect that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. boosted its position in GH Research PLC (NASDAQ:GHRS) by 11.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,251,714 shares of the company’s stock after acquiring an additional 664,381 shares during the period. RA Capital Management L.P. owned 12.02% of GH Research worth $66,643,000 at the end of the most recent reporting period. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).